Symbols / DBVT $21.00 -0.28% DBV Technologies S.A.
DBVT Chart
About
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.24B |
| Enterprise Value | 4.77B | Income | -146.95M | Sales | 5.64M |
| Book/sh | 3.58 | Cash/sh | 0.82 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -80.17 | PEG | — |
| P/S | 220.61 | P/B | 5.87 | P/C | — |
| EV/EBITDA | -33.19 | EV/Sales | 847.06 | Quick Ratio | 3.62 |
| Current Ratio | 3.67 | Debt/Eq | 3.87 | LT Debt/Eq | — |
| EPS (ttm) | -5.25 | EPS next Y | -0.26 | EPS Growth | — |
| Revenue Growth | 26.20% | Earnings | 2026-04-29 | ROA | -61.40% |
| ROE | -149.83% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -69.85% | Profit Margin | 0.00% | Shs Outstand | 59.21M |
| Shs Float | 149.39M | Short Float | 3.07% | Short Ratio | 6.00 |
| Short Interest | — | 52W High | 26.18 | 52W Low | 6.46 |
| Beta | -0.20 | Avg Volume | 338.95K | Volume | 5.59K |
| Target Price | $40.11 | Recom | Buy | Prev Close | $21.06 |
| Price | $21.00 | Change | -0.28% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-27 | main | Citizens | Market Outperform → Market Outperform | $47 |
| 2026-03-27 | reit | Guggenheim | Buy → Buy | $51 |
| 2025-12-17 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-12-17 | main | Cantor Fitzgerald | Overweight → Overweight | $48 |
| 2025-12-17 | main | Citizens | Market Outperform → Market Outperform | $45 |
| 2025-12-17 | main | Guggenheim | Buy → Buy | $51 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-12-15 | init | Cantor Fitzgerald | — → Overweight | $42 |
| 2025-12-03 | init | Guggenheim | — → Buy | $35 |
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-06-26 | reit | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2025-05-27 | main | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2025-05-05 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-05-01 | main | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2025-03-04 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $10 |
| 2025-01-10 | reit | JMP Securities | Market Outperform → Market Outperform | $10 |
| 2024-12-10 | reit | JMP Securities | Market Outperform → Market Outperform | $10 |
| 2024-10-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-07-31 | main | JMP Securities | Market Outperform → Market Outperform | $5 |
- Trading the Move, Not the Narrative: (DBVT) Edition - news.stocktradersdaily.com Mon, 06 Apr 2026 02
- DBV Technologies lists 296M shares, 295.9M net voting rights - stocktitan.net hu, 02 Apr 2026 20
- DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Friday - MarketBeat Fri, 03 Apr 2026 05
- DBV Technologies S.A. (DBVT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade hu, 02 Apr 2026 21
- DBV Technologies stock soars after positive Phase 3 trial results - Investing.com ue, 16 Dec 2025 08
- $DBVT stock is up 20% today. Here's what we see in our data. - quiverquant.com Mon, 08 Dec 2025 08
- DBV Technologies: A Tough Nut To Crack In A Shrinking Market (NASDAQ:DBVT) - Seeking Alpha Mon, 30 Mar 2026 17
- LifeSci Capital Maintains DBV Technologies(DBVT.US) With Buy Rating, Cuts Target Price to $46 - moomoo.com Wed, 01 Apr 2026 21
- DBV Technologies Sets Stage For 'Swift' Success As Breakthrough Peanut Patch Nears FDA Submission - Sahm Fri, 27 Mar 2026 07
- DBVT Stock Rockets on Positive Peanut Allergy Patch Trial - RagingBull Wed, 17 Dec 2025 08
- Peanut patch developer DBV says cash funds operations into Q2 2027 - stocktitan.net hu, 26 Mar 2026 07
- DBV Technologies (NASDAQ:DBVT) Shares Gap Down - What's Next? - MarketBeat Wed, 11 Mar 2026 07
- $DBVT stock is down 12% today. Here's what we see in our data. - quiverquant.com Mon, 05 Jan 2026 08
- DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally (NASDAQ:DBVT) - Seeking Alpha hu, 11 Dec 2025 08
- DBV files annual report in the US and France, including buyback plan - stocktitan.net hu, 26 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
147.05
+26.13%
|
116.59
+52.54%
|
76.43
-20.90%
|
96.63
|
| Research And Development |
|
116.68
+30.60%
|
89.34
+48.35%
|
60.22
-20.28%
|
75.54
|
| Selling General And Administration |
|
28.28
+18.54%
|
23.85
+4.73%
|
22.78
+29.69%
|
17.56
|
| Selling And Marketing Expense |
|
—
|
—
|
—
|
—
|
| General And Administrative Expense |
|
28.28
+18.54%
|
23.85
+4.73%
|
22.78
+29.69%
|
17.56
|
| Salaries And Wages |
|
17.24
+43.27%
|
12.03
-2.52%
|
12.34
+13.01%
|
10.92
|
| Other Gand A |
|
11.04
-6.62%
|
11.82
+13.30%
|
10.43
+57.11%
|
6.64
|
| Other Operating Expenses |
|
—
|
-0.01
+99.93%
|
-6.96
-896.57%
|
0.87
|
| Total Expenses |
|
147.05
+26.13%
|
116.59
+52.54%
|
76.43
-20.90%
|
96.63
|
| Operating Income |
|
-147.05
-26.13%
|
-116.59
-52.54%
|
-76.43
+20.90%
|
-96.63
|
| Total Operating Income As Reported |
|
-147.06
-26.13%
|
-116.59
-52.54%
|
-76.43
+20.90%
|
-96.63
|
| EBITDA |
|
-139.32
-27.77%
|
-109.05
-62.10%
|
-67.27
+19.40%
|
-83.47
|
| Normalized EBITDA |
|
-139.32
-27.77%
|
-109.05
-62.10%
|
-67.27
+19.40%
|
-83.47
|
| Reconciled Depreciation |
|
3.19
+445.30%
|
-0.93
+93.39%
|
-14.00
-206.35%
|
13.16
|
| EBIT |
|
-147.05
-26.13%
|
-116.59
-52.54%
|
-76.43
+20.90%
|
-96.63
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Pretax Income |
|
-146.46
-28.62%
|
-113.86
-56.58%
|
-72.72
+24.41%
|
-96.20
|
| Net Non Operating Interest Income Expense |
|
0.60
-77.95%
|
2.73
-26.60%
|
3.71
+769.79%
|
0.43
|
| Net Interest Income |
|
0.60
-77.95%
|
2.73
-26.60%
|
3.71
+769.79%
|
0.43
|
| Other Income Expense |
|
—
|
—
|
—
|
—
|
| Tax Provision |
|
0.49
+792.73%
|
0.06
+685.71%
|
0.01
-90.00%
|
0.07
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+249900.00%
|
0.00
-85.71%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Net Income From Continuing Operation Net Minority Interest |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Net Income From Continuing And Discontinued Operation |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Net Income Continuous Operations |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Normalized Income |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Net Income Common Stockholders |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Diluted EPS |
|
—
|
-5.85
-53.95%
|
-3.80
+38.71%
|
-6.20
|
| Basic EPS |
|
—
|
-5.85
-53.95%
|
-3.80
+38.71%
|
-6.20
|
| Basic Average Shares |
|
—
|
19.47
+2.34%
|
19.02
+22.48%
|
15.53
|
| Diluted Average Shares |
|
—
|
19.47
+2.34%
|
19.02
+22.48%
|
15.53
|
| Diluted NI Availto Com Stockholders |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Depreciation Amortization Depletion Income Statement |
|
7.73
+2.47%
|
7.54
-17.64%
|
9.16
+9.46%
|
8.37
|
| Depreciation And Amortization In Income Statement |
|
7.73
+2.47%
|
7.54
-17.64%
|
9.16
+9.46%
|
8.37
|
| Other Taxes |
|
-5.64
-35.94%
|
-4.15
+52.70%
|
-8.77
-53.31%
|
-5.72
|
| Total Other Finance Cost |
|
-0.60
+77.95%
|
-2.73
+26.60%
|
-3.71
-769.79%
|
-0.43
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
233.72
+255.96%
|
65.66
-64.12%
|
182.99
-25.77%
|
246.52
|
| Current Assets |
|
212.94
+379.73%
|
44.39
-72.07%
|
158.91
-28.76%
|
223.07
|
| Cash Cash Equivalents And Short Term Investments |
|
194.17
+498.25%
|
32.46
-77.04%
|
141.37
-32.42%
|
209.19
|
| Cash And Cash Equivalents |
|
194.17
+498.25%
|
32.46
-77.04%
|
141.37
-32.42%
|
209.19
|
| Cash Equivalents |
|
67.05
|
0.00
-100.00%
|
130.84
-26.94%
|
179.09
|
| Cash Financial |
|
127.12
+291.66%
|
32.46
+208.22%
|
10.53
-65.02%
|
30.10
|
| Receivables |
|
16.15
+55.40%
|
10.39
-32.73%
|
15.45
+37.92%
|
11.20
|
| Accounts Receivable |
|
—
|
—
|
0.00
|
0.00
|
| Other Receivables |
|
1.58
-19.50%
|
1.96
+44.79%
|
1.35
-10.04%
|
1.50
|
| Taxes Receivable |
|
14.57
+72.81%
|
8.43
-40.17%
|
14.09
+45.36%
|
9.70
|
| Prepaid Assets |
|
2.63
+70.54%
|
1.54
-26.72%
|
2.10
-21.53%
|
2.68
|
| Other Current Assets |
|
—
|
—
|
-0.00
-200.00%
|
0.00
|
| Total Non Current Assets |
|
20.77
-2.33%
|
21.27
-11.63%
|
24.07
+2.67%
|
23.44
|
| Net PPE |
|
14.95
-11.09%
|
16.81
-6.24%
|
17.93
+1.81%
|
17.61
|
| Gross PPE |
|
37.82
+10.15%
|
34.34
-6.90%
|
36.88
+13.84%
|
32.40
|
| Accumulated Depreciation |
|
-22.88
-30.51%
|
-17.53
+7.52%
|
-18.95
-28.17%
|
-14.79
|
| Properties |
|
—
|
—
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
3.33
+3.52%
|
3.21
|
| Machinery Furniture Equipment |
|
3.53
+13.73%
|
3.10
-31.52%
|
4.53
+159.90%
|
1.74
|
| Construction In Progress |
|
1.16
-2.45%
|
1.19
-18.95%
|
1.46
-67.28%
|
4.47
|
| Other Properties |
|
33.14
+10.27%
|
30.05
-2.72%
|
30.89
+34.47%
|
22.97
|
| Goodwill And Other Intangible Assets |
|
0.02
-45.00%
|
0.04
-31.03%
|
0.06
+480.00%
|
0.01
|
| Investments And Advances |
|
5.19
+20.34%
|
4.31
|
—
|
1.77
|
| Non Current Accounts Receivable |
|
0.62
+458.56%
|
0.11
|
—
|
0.31
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
1.77
|
| Other Non Current Assets |
|
-0.00
+0.00%
|
-0.00
-100.02%
|
6.08
+62.70%
|
3.74
|
| Total Liabilities Net Minority Interest |
|
64.95
+69.71%
|
38.27
-10.58%
|
42.80
-17.80%
|
52.06
|
| Current Liabilities |
|
58.02
+86.36%
|
31.14
-16.61%
|
37.34
+26.48%
|
29.52
|
| Payables And Accrued Expenses |
|
41.53
+86.92%
|
22.22
-5.55%
|
23.52
+61.77%
|
14.54
|
| Payables |
|
41.53
+86.92%
|
22.22
-5.55%
|
23.52
+61.77%
|
14.54
|
| Accounts Payable |
|
40.94
+85.83%
|
22.03
-5.45%
|
23.30
+61.00%
|
14.47
|
| Total Tax Payable |
|
0.59
+214.89%
|
0.19
-15.70%
|
0.22
+223.19%
|
0.07
|
| Current Debt And Capital Lease Obligation |
|
2.58
+72.33%
|
1.50
-26.00%
|
2.03
-32.99%
|
3.02
|
| Current Debt |
|
1.47
+73.52%
|
0.85
-4.19%
|
0.88
-21.93%
|
1.13
|
| Other Current Borrowings |
|
1.47
+73.52%
|
0.85
-4.19%
|
0.88
-21.93%
|
1.13
|
| Current Capital Lease Obligation |
|
1.12
+70.80%
|
0.65
-42.83%
|
1.14
-39.60%
|
1.89
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
2.14
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
2.14
|
| Other Current Liabilities |
|
13.91
+87.53%
|
7.42
-37.08%
|
11.79
+20.07%
|
9.82
|
| Total Non Current Liabilities Net Minority Interest |
|
6.92
-2.97%
|
7.13
+30.68%
|
5.46
-75.78%
|
22.54
|
| Long Term Debt And Capital Lease Obligation |
|
5.41
-14.10%
|
6.30
+39.13%
|
4.53
+301.60%
|
1.13
|
| Long Term Capital Lease Obligation |
|
5.41
-14.10%
|
6.30
+39.13%
|
4.53
+301.60%
|
1.13
|
| Other Non Current Liabilities |
|
1.51
+80.67%
|
0.84
-10.28%
|
0.93
-95.64%
|
21.42
|
| Stockholders Equity |
|
168.77
+516.22%
|
27.39
-80.46%
|
140.19
-27.91%
|
194.45
|
| Common Stock Equity |
|
168.77
+516.22%
|
27.39
-80.46%
|
140.19
-27.91%
|
194.45
|
| Capital Stock |
|
26.91
+130.98%
|
11.65
+6.19%
|
10.97
+2.35%
|
10.72
|
| Common Stock |
|
26.91
+130.98%
|
11.65
+6.19%
|
10.97
+2.35%
|
10.72
|
| Share Issued |
|
235.67
+129.15%
|
102.85
+6.65%
|
96.43
+2.44%
|
94.14
|
| Ordinary Shares Number |
|
235.60
+129.67%
|
102.58
+6.62%
|
96.21
+2.36%
|
93.99
|
| Treasury Shares Number |
|
0.07
-72.02%
|
0.27
+19.68%
|
0.22
+48.86%
|
0.15
|
| Additional Paid In Capital |
|
541.25
+71.49%
|
315.61
-16.39%
|
377.47
-17.62%
|
458.22
|
| Retained Earnings |
|
-393.13
-37.28%
|
-286.38
-19.89%
|
-238.86
+7.98%
|
-259.58
|
| Gains Losses Not Affecting Retained Earnings |
|
-5.43
+55.46%
|
-12.19
-49.98%
|
-8.13
+41.09%
|
-13.80
|
| Treasury Stock |
|
0.83
-36.29%
|
1.31
+3.64%
|
1.26
+13.89%
|
1.11
|
| Other Equity Adjustments |
|
0.50
-45.08%
|
0.91
+21.97%
|
0.74
-4.99%
|
0.78
|
| Total Equity Gross Minority Interest |
|
168.77
+516.24%
|
27.39
-80.46%
|
140.19
-27.91%
|
194.45
|
| Total Capitalization |
|
168.77
+516.22%
|
27.39
-80.46%
|
140.19
-27.91%
|
194.45
|
| Working Capital |
|
154.92
+1069.02%
|
13.25
-89.10%
|
121.58
-37.19%
|
193.55
|
| Invested Capital |
|
170.24
+502.95%
|
28.23
-79.99%
|
141.07
-27.87%
|
195.59
|
| Total Debt |
|
7.99
+2.53%
|
7.80
+18.98%
|
6.55
+57.83%
|
4.15
|
| Capital Lease Obligations |
|
6.53
-6.11%
|
6.95
+22.59%
|
5.67
+87.69%
|
3.02
|
| Net Tangible Assets |
|
168.75
+517.04%
|
27.35
-80.48%
|
140.13
-27.93%
|
194.44
|
| Tangible Book Value |
|
168.75
+517.04%
|
27.35
-80.48%
|
140.13
-27.93%
|
194.44
|
| Available For Sale Securities |
|
5.19
+20.34%
|
4.31
|
—
|
1.77
|
| Foreign Currency Translation Adjustments |
|
-5.93
+54.75%
|
-13.10
-47.64%
|
-8.87
+39.16%
|
-14.58
|
| Investmentin Financial Assets |
|
5.19
+20.34%
|
4.31
|
—
|
1.77
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-121.18
-15.99%
|
-104.47
-31.16%
|
-79.65
-43.09%
|
-55.67
|
| Cash Flow From Continuing Operating Activities |
|
-121.18
-15.99%
|
-104.47
-31.16%
|
-79.65
-43.09%
|
-55.67
|
| Net Income From Continuing Operations |
|
-146.95
-28.99%
|
-113.92
-56.64%
|
-72.73
+24.46%
|
-96.27
|
| Depreciation Amortization Depletion |
|
3.19
+445.30%
|
-0.93
+93.39%
|
-14.00
-206.35%
|
13.16
|
| Depreciation |
|
3.19
+445.30%
|
-0.93
+93.39%
|
-14.00
-206.35%
|
13.16
|
| Depreciation And Amortization |
|
3.19
+445.30%
|
-0.93
+93.39%
|
-14.00
-206.35%
|
13.16
|
| Other Non Cash Items |
|
-0.22
-7133.33%
|
-0.00
-113.04%
|
0.02
+560.00%
|
-0.01
|
| Pension And Employee Benefit Expense |
|
—
|
0.00
-100.00%
|
0.08
-27.62%
|
0.10
|
| Stock Based Compensation |
|
5.39
+16.60%
|
4.62
-23.24%
|
6.02
+19.76%
|
5.03
|
| Asset Impairment Charge |
|
16.06
+1057.20%
|
1.39
|
—
|
—
|
| Operating Gains Losses |
|
—
|
—
|
0.08
-27.62%
|
0.10
|
| Change In Working Capital |
|
1.34
-69.29%
|
4.36
+357.92%
|
0.95
-95.73%
|
22.32
|
| Change In Receivables |
|
—
|
—
|
0.00
|
0.00
|
| Changes In Account Receivables |
|
—
|
—
|
0.00
|
0.00
|
| Change In Inventory |
|
-16.06
-1057.20%
|
-1.39
|
0.00
|
0.00
|
| Change In Payables And Accrued Expense |
|
15.78
+5702.57%
|
0.27
-96.77%
|
8.42
+143.63%
|
3.46
|
| Change In Payable |
|
15.78
+5702.57%
|
0.27
-96.77%
|
8.42
+143.63%
|
3.46
|
| Change In Account Payable |
|
15.78
+5702.57%
|
0.27
-96.77%
|
8.42
+143.63%
|
3.46
|
| Change In Other Working Capital |
|
-0.20
-141.86%
|
0.48
-70.82%
|
1.66
+173.90%
|
-2.25
|
| Change In Other Current Assets |
|
-4.70
-201.51%
|
4.63
+221.98%
|
-3.79
-118.11%
|
20.96
|
| Change In Other Current Liabilities |
|
6.52
+1681.69%
|
0.37
+106.86%
|
-5.33
-3609.21%
|
0.15
|
| Investing Cash Flow |
|
-1.37
-80.85%
|
-0.76
+6.31%
|
-0.81
-708.00%
|
-0.10
|
| Cash Flow From Continuing Investing Activities |
|
-1.37
-80.85%
|
-0.76
+6.31%
|
-0.81
-716.16%
|
-0.10
|
| Net PPE Purchase And Sale |
|
-0.53
+77.25%
|
-2.34
-245.35%
|
-0.68
+9.25%
|
-0.75
|
| Purchase Of PPE |
|
-0.53
+77.25%
|
-2.34
-245.35%
|
-0.68
+10.21%
|
-0.75
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Capital Expenditure |
|
-0.54
+77.02%
|
-2.34
-245.79%
|
-0.68
+10.21%
|
-0.75
|
| Net Investment Purchase And Sale |
|
—
|
—
|
-0.13
-120.25%
|
0.65
|
| Purchase Of Investment |
|
—
|
—
|
-0.28
-131.71%
|
-0.12
|
| Sale Of Investment |
|
—
|
—
|
0.15
-80.00%
|
0.77
|
| Net Intangibles Purchase And Sale |
|
-0.01
-100.00%
|
-0.00
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
-0.01
-100.00%
|
-0.00
|
0.00
|
0.00
|
| Net Other Investing Changes |
|
-0.83
-152.46%
|
1.58
+1309.16%
|
-0.13
-13000.00%
|
-0.00
|
| Financing Cash Flow |
|
276.18
+46949.74%
|
0.59
-91.33%
|
6.77
-96.51%
|
194.12
|
| Cash Flow From Continuing Financing Activities |
|
276.18
+46949.74%
|
0.59
-91.33%
|
6.77
-96.51%
|
194.12
|
| Net Common Stock Issuance |
|
276.18
+46949.74%
|
0.59
-91.33%
|
6.77
-96.52%
|
194.59
|
| Common Stock Payments |
|
—
|
-0.05
+69.48%
|
-0.15
|
—
|
| Repurchase Of Capital Stock |
|
—
|
-0.05
+69.48%
|
-0.15
|
—
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-0.47
|
| Changes In Cash |
|
153.63
+246.81%
|
-104.64
-42.00%
|
-73.69
-153.26%
|
138.35
|
| Effect Of Exchange Rate Changes |
|
8.08
+289.32%
|
-4.27
-172.75%
|
5.87
+190.81%
|
-6.46
|
| Beginning Cash Position |
|
32.46
-77.04%
|
141.37
-32.42%
|
209.19
+170.62%
|
77.30
|
| End Cash Position |
|
194.17
+498.25%
|
32.46
-77.04%
|
141.37
-32.42%
|
209.19
|
| Free Cash Flow |
|
-121.72
-13.95%
|
-106.81
-32.97%
|
-80.33
-42.38%
|
-56.42
|
| Common Stock Issuance |
|
276.18
+43461.83%
|
0.63
-90.84%
|
6.92
-96.44%
|
194.59
|
| Issuance Of Capital Stock |
|
276.18
+43461.83%
|
0.63
-90.84%
|
6.92
-96.44%
|
194.59
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-26 View
- 10-K2026-03-26 View
- 8-K2026-03-02 View
- 42026-02-02 View
- 8-K2026-01-20 View
- 42026-01-14 View
- 42025-12-19 View
- 8-K2025-12-16 View
- 42025-11-25 View
- 42025-11-24 View
- 42025-11-24 View
- 42025-11-24 View
- 8-K2025-10-30 View
- 8-K2025-10-29 View
- 10-Q2025-10-28 View
- 8-K2025-09-18 View
- 8-K2025-09-05 View
- 42025-07-31 View
- 8-K2025-07-29 View
- 10-Q2025-07-29 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|